ArticleCase reports in nephrology and dialysis
Collaborative Management of Hyperkalemia in Patients with Complex Heart Failure.
Article in Case reports in nephrology and dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of this study was to highlight the benefits and provide a framework for integrated multispecialty team involvement in the management of hyperkalemia in patients with heart failure (HF) and kidney disease and to ensure that patients receive optimal medical therapy to improve their clinical outcomes. Case Presentation: This report highlights a hypothetical "complex" case of a patient with an acute HF decompensation who experiences hyperkalemia following up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Two hypothetical scenarios for treatment management are discussed; in the first, providers down-titrate guideline-directed RAASi to avoid hyperkalemia, whereas in the second, providers take a collaborative interdisciplinary approach to manage hyperkalemia directly with the aim of avoiding RAASi down-titration. In the first typical management scenario, down-titration of guideline-directed RAASi to prevent increases in serum potassium (serum K Conclusion: Collaborative multispecialty team management of HF patients may enable successful management of hyperkalemia without the need for discontinuation of guideline-directed RAASi therapy. Collaboration could extend to regular virtual or face-to-face cardiorenal clinics, where complex cases can be discussed, and local guidelines and processes can be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.